https://www.selleckchem.com/pr....oducts/empagliflozin
Around 40% of patients were responders and were able to engage in sexual intercourse. Patients in placebo group did not experience significant improvement (p=0.264). It was noted that at the 2nd week and 3rd months after treatment, there was no statistically significant difference in the improvement of these parameters in BTX-100 and BTX-50 groups (p0.05). In the 6th month, there was a statistically significant difference between the aforementioned groups in favor of BTX-100 (p0.01). Only one-time ICI of BTX (50 U
Like
Comment
Share
